|
| Press Releases |
|
 |
|
| Monday, October 21, 2024 |
|
|
China Medical System: First Ruxolitinib Cream's Prescriptions for Vitiligo Issued in the Greater Bay Area |
| China Medical System Holdings Limited (the "Group" or "CMS") is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital. more info >> |
|
| Tuesday, September 24, 2024 |
|
|
China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China |
| China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA). more info >> |
|
| Friday, August 16, 2024 |
|
|
China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023 |
| On August 15, 2024, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023. more info >> |
|
| Monday, August 5, 2024 |
|
|
China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China |
| China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 30 July 2024, the New Drug Application (NDA) for an additional indication of Methotrexate Injection (the "Product") has been approved by the National Medical Products Administration of China (NMPA). more info >> |
|
| Tuesday, July 16, 2024 |
|
|
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating |
| In July 2024, China Medical System Holdings Limited ("CMS" or the "Group") has once again been recognized for its outstanding performance and continuous progress in sustainable development. more info >> |
|
| Tuesday, June 25, 2024 |
|
|
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China |
| On June 25, China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the "Product") in atopic dermatitis ("AD") in China. more info >> |
|
| Tuesday, June 18, 2024 |
|
|
China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China |
| more info >> |
|
| Tuesday, April 23, 2024 |
|
|
China Medical System: New Drug Application of Desidustat Tablets Accepted in China |
| China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that on 22 April 2024, the New Drug Application (NDA) of Desidustat Tablets ("Desidustat Tablets" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA). more info >> |
|
| Monday, April 1, 2024 |
|
|
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia |
| more info >> |
|
| Thursday, March 28, 2024 |
|
|
China Medical System (867.HK) 2023 Annual Results: Despite of the Temporary Financial Performance Pressure, Fresh Catalysts Emerged from Successive Innovation Breakthroughs |
| more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Understand The Type of Credit Cards Offered By Citi And Find the Most Suitable One
Nov 17, 2024 13:30 HKT/SGT
|
|
|
Cropmate Sets to Raise RM42.0 Million from ACE Market IPO 
Nov 17, 2024 13:00 HKT/SGT
|
|
|
COP29: Indonesian Special Envoy Hashim Djojohadikusumo Announces EUR 1,2 Billion Green Funding
Nov 16, 2024 17:00 HKT/SGT
|
|
|
Military Metals Completes Acquisition of Brownfield Antimony Projects in Europe
Nov 16, 2024 12:39 HKT/SGT
|
|
|
Military Metals Announces LOI to Acquire Past-Producing Last Chance Antimony-Gold Property, near Round Mountain, Nevada
Nov 16, 2024 02:02 HKT/SGT
|
|
|
Doubleview Gold Corp Announces Closing of Private Placement for Total of $4,027,000
Nov 16, 2024 01:10 HKT/SGT
|
|
|
Quranium Launches QSafe Wallet with Core Layer (L1) Testnet: The Uncrackable Solution for Blockchain Security
Nov 16, 2024 01:00 HKT/SGT
|
|
|
Quranium Node Pre-sale Unveiled: Be Part of the Quantum-Uncrackable Revolution
Nov 16, 2024 01:00 HKT/SGT
|
|
|
TransNusa Signs MOU on MRO Services with AIROD
Nov 15, 2024 22:00 HKT/SGT
|
|
|
SINCETHEN to Open New Two-Story Showroom at Liangcang Art Park in Hangzhou, China
Nov 15, 2024 19:00 HKT/SGT
|
|
|
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony of LNG-Powered Roll-on/Roll-off Ship TRANS HARMONY EMERALD in Shimonoseki
Nov 15, 2024 18:58 JST
|
|
|
WFM Asia Announces Brand Evolution
Nov 15, 2024 17:12 HKT/SGT
|
|
|
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 17:33 JST
|
|
|
COP29: PLN Encourages Global Collaboration for Energy Transition Towards Sustainable Energy Self-Sufficiency
Nov 15, 2024 16:00 HKT/SGT
|
|
|
APTEXPO 2024 concludes on a high note, offering numerous innovation opportunities for decision-makers across the Asia Pacific's fashion and supply chain sectors
Nov 15, 2024 15:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
